Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 27

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 27
---
 the event that our Common Stock price does not exceed the exercise price of the April 2025 Warrants during the period when such April 2025 Warrants are exercisable, such April 2025 Warrants may not have any value. Furthermore, each April 2025 Warrant will expire five years from its date of issuance.

Except as set forth in the April 2025 Warrants and Pre-Funded Warrants, Holders of the April 2025 Warrants and Pre-Funded Warrants will not have rights of holders of our shares of Common Stock until such April 2025 Warrants and Pre-Funded Warrants are exercised.

Except as set forth in the April 2025 Warrants and Pre-Funded Warrants the April 2025 Warrants and Pre-Funded Warrants in this offering do not confer any rights of share ownership on their holders, but rather merely represent the right to acquire shares of our Common Stock at a fixed price. Until holders of April 2025 Warrants and Pre-Funded Warrants acquire shares of our Common Stock upon exercise of the April 2025 Warrants and Pre-Funded Warrants, as applicable, holders of April 2025 Warrants and Pre-Funded Warrants will have no rights with respect to our shares of Common Stock underlying such April 2025 Warrants and Pre-Funded Warrants.

| 10 |

If we are required to obtain Warrant Stockholder Approval, until we are able to receive such approval the April 2025 Warrants will not be exercisable, and if we are unable to obtain such approval the April 2025 Warrants will have no value.

If we are required to obtain Warrant Stockholder Approval, the April 2025 Warrants will not be exercisable until, and unless, we obtain the Warrant Stockholder Approval from our stockholders. While we intend to promptly seek stockholder approval, if required, there is no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the Warrant Stockholder Approval, the April 2025 Warrants will have no value. In addition, we will incur substantial cost, and management will devote substantial time and attention, in attempting to obtain the Warrant Stockholder Approval.

If we do not maintain a current and effective prospectus relating to the Common Stock issuable upon exercise of the April 2025 Warrants and Pre-Funded Warrants, public holders will only be able to exercise such April 2025 Warrants and